已发表论文

同时放化疗联合抗 PD-1 治疗 HER2 阴性晚期胃腺癌持久反应:一个病例报告

 

Authors Yu S, Cai L, Lin F, Wu X, Zhang C, Liu X, Li W

Received 1 July 2019

Accepted for publication 3 September 2019

Published 19 September 2019 Volume 2019:12 Pages 7691—7698

DOI https://doi.org/10.2147/OTT.S221436

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Shashank Kaushik (PT)

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava

Abstract: Advanced gastric cancer (AGC) is difficult to treat with poor prognosis. Despite various possible treatments, the median survival time of such patients remains unsatisfactory. Therefore, new therapeutic approaches or combinations need to be further explored. We herein reported a case of a 54-year-old male patient who was initially diagnosed with HER2-negative advanced gastric cancer. Based on previous studies and patient’s desire, we made a therapeutic plan: the combination of concurrent radiochemotherapy and immune checkpoint blockade therapy. After about 4 months of combined therapy, the patient showed satisfactory complete response to tumor lesions even metastatic lesions (CR, disappearance of all target lesions). In summary, the combination of concurrent SOX regimen chemotherapy, stomach radiotherapy and PD-1 antibody immunotherapy is effective in the treatment of advanced gastric cancer.
Keywords: PD-1 antibody immunotherapy, radiotherapy, advanced gastric cancer, SOX regimen chemotherapy, concurrent therapy




Figure 3 Treatment effect images of patients before and...